Restrictions on experimental treatments will likely have a significant impact on pharmaceutical companies which have, in recent years, bought up rights to experimental drugs created in China

Japan, India, South Korea and Taiwan, who all export products to the US from these three industries, have already been stumbling under the pressure of increasing tariff threats

A fresh crackdown on the country's medical and pharmaceutical sectors, set to last a year, has convinced investors that it may be best to buy the state and sell private sector holdings